Associated tags: Infection, FYB207, SCG, Vaccine, Patient, Cancer, Pharmaceutical industry, ISCT, Coronavirus, Virology, Institute of technology, Conditional sentence, Severe acute respiratory syndrome coronavirus 2, WKN, Human papillomavirus infection, Hepatitis B, ACE2, SCG Cell Therapy Pte Ltd, Helicobacter pylori, Biotechnology
Retrieved on:
Wednesday, April 17, 2024
Public sector,
Memorandum,
Good manufacturing practice,
A*STAR,
SCG,
IMCB,
Innovation,
Agency,
STAR,
BTI,
Automation,
Environment,
Therapy,
Patient,
IPSC,
Cell biology,
Regenerative medicine,
GMP,
TCR,
Cancer,
CGMP,
Pharmaceutical industry Collaboration aims to develop scalable GMP-grade iPSC manufacturing processes and therapeutic candidates to facilitate research leading to translation of novel cellular immunotherapies.
Key Points:
- Collaboration aims to develop scalable GMP-grade iPSC manufacturing processes and therapeutic candidates to facilitate research leading to translation of novel cellular immunotherapies.
- Launch of the joint labs builds on existing license, research collaboration and Memorandum of Understanding between SCG Cell Therapy and A*STAR.
- SINGAPORE, April 16, 2024 /PRNewswire/ -- SCG Cell Therapy (SCG) and the Agency for Science, Technology and Research (A*STAR) announced the launch joint laboratories for cellular immunotherapies.
- Through this collaboration with SCG Cell Therapy, we aim to accelerate the translation of iPSC research into clinically viable therapies and strengthen Singapore's position as a global leader in cell therapy innovation.
ISCT,
Serum,
Cell proliferation,
Infection,
Hepatitis B virus,
SCG,
HBsAg,
Patient,
Cancer,
Cell,
Epitope,
HBV,
HCC,
International Society,
ILC,
Pharmaceutical industry,
Vaccine "The clinical data shows exceptional efficacy of this novel TCR-T cell therapy.
Key Points:
- "The clinical data shows exceptional efficacy of this novel TCR-T cell therapy.
- SCG101 is an autologous TCR-T cell therapy targeting specific hepatitis B surface antigen (HBsAg) epitopes.
- In June 2022, SCG Cell Therapy presented the first clinical proof-of-concept data demonstrating the mechanism of action of a HBsAg-specific TCR-T cell therapy, SCG101, at the International Liver Congress (ILC) 2022.
- The data showed precise target engagement and cell proliferation, and demonstrated antiviral activity and tumour control.
Retrieved on:
Tuesday, October 19, 2021
Biotechnology,
Institute,
Cancer,
SCG,
COVID-19,
Ophthalmology,
Marketing,
ISIN,
Hepatitis B,
Helicobacter pylori,
Virology,
Institute of technology,
Coronavirus,
Severe acute respiratory syndrome coronavirus 2,
WKN,
CEO,
Patient,
Human papillomavirus infection,
Conditional sentence,
Infection,
ACE2,
Pharmaceutical industry,
Vaccine,
FYB207,
SCG Cell Therapy Pte Ltd,
FYB207,
SCG CELL THERAPY PTE LTD Under the terms of the agreement, SCG has access to Formycon's ACE2 fusion protein technology and has acquired an exclusive license to develop, manufacture and commercialize FYB207 in the Asia-Pacific (APAC) region (except Japan).
Key Points:
- Under the terms of the agreement, SCG has access to Formycon's ACE2 fusion protein technology and has acquired an exclusive license to develop, manufacture and commercialize FYB207 in the Asia-Pacific (APAC) region (except Japan).
- The APAC region is home to about 60% of the world's population and is the world's second largest healthcare market.
- SCG will be responsible for the development and manufacturing of FYB207 in Asia, and if approved, bring this innovative COVID-19 drug to patients and healthcare providers in the Asia-Pacific region."
- Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a COVID-19 drug FYB207.
